Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Gierisch, JM, Coeytaux, RR, Urrutia, RP, Havrilesky, LJ, Moorman, PG, Lowery, WJ, Dinan, M, McBroom, AJ, Hasselblad, V, Sanders, GD, and Myers, ER. "Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 22, no. 11 (November 2013): 1931-1943. (Review)

Full Text

Barnett, JC, Alvarez Secord, A, Cohn, DE, Leath, CA, Myers, ER, and Havrilesky, LJ. "Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer." Cancer 119, no. 20 (October 15, 2013): 3653-3661.

Full Text

Havrilesky, LJ, Chino, JP, and Myers, ER. "How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis." Gynecol Oncol 131, no. 1 (October 2013): 140-146.

Full Text

Morgan, RJ, Alvarez, RD, Armstrong, DK, Burger, RA, Chen, L-M, Copeland, L, Crispens, MA, Gershenson, DM, Gray, HJ, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Powell, MA, Remmenga, SW, Sabbatini, P, Santoso, JT, Schink, JC, Teng, N, Werner, TL, Dwyer, MA, Hughes, M, and National comprehensive cancer networks, . "Ovarian cancer, version 2.2013." J Natl Compr Canc Netw 11, no. 10 (October 1, 2013): 1199-1209.

Scholars@Duke

Morgan, RJ, Alvarez, RD, Armstrong, DK, Burger, RA, Chen, L-M, Copeland, L, Crispens, MA, Gershenson, DM, Gray, HJ, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Powell, MA, Remmenga, SW, Sabbatini, P, Santoso, JT, Schink, JC, Teng, N, Werner, TL, Dwyer, MA, Hughes, M, and National comprehensive cancer networks, . "Ovarian cancer, version 2.2013." Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 10 (October 2013): 1199-1209.

Full Text

Lopez-Acevedo, M, Lowery, WJ, Lowery, AW, Lee, PS, and Havrilesky, LJ. "Palliative and hospice care in gynecologic cancer: a review." Gynecol Oncol 131, no. 1 (October 2013): 215-221. (Review)

Full Text

Tergas, AI, Havrilesky, LJ, Fader, AN, Guntupalli, SR, Huh, WK, Massad, LS, and Rimel, BJ. "Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer." Gynecol Oncol 130, no. 3 (September 2013): 421-425.

Full Text

Lowery, WJ, Lowery, AW, Barnett, JC, Lopez-Acevedo, M, Lee, PS, Secord, AA, and Havrilesky, L. "Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer." Gynecol Oncol 130, no. 3 (September 2013): 426-430.

Full Text

Phippen, NT, Leath, CA, Miller, CR, Lowery, WJ, Havrilesky, LJ, and Barnett, JC. "Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?." Gynecol Oncol 130, no. 2 (August 2013): 317-322.

Full Text

Peragallo Urrutia, R, Coeytaux, RR, McBroom, AJ, Gierisch, JM, Havrilesky, LJ, Moorman, PG, Lowery, WJ, Dinan, M, Hasselblad, V, Sanders, GD, and Myers, ER. "Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis." Obstetrics and Gynecology 122, no. 2 Pt 1 (August 1, 2013): 380-389. (Review)

Scholars@Duke

Pages